Circassia Pharmaceuticals

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Circassia Pharmaceuticals plc
Public limited company
Traded as LSECIR
Industry Pharmaceuticals
Founded 2006
Headquarters Oxford, United Kingdom
Key people
Francesco Granata, (Chairman)
Steven Harris, (CEO)
Revenue £10.8 million (2015)[1]
£(66.4) million (2015)[1]
£(50.0) million (2015)[1]
Website www.circassia.co.uk

Circassia Pharmaceuticals is a specialty biopharmaceutical company developing a range of immunotherapies. It is listed on the London Stock Exchange.

History[edit]

The company was founded by Steve Harris and Charles Swingland in 2006.[2] It was the subject of an Initial Public Offering in March 2014.[3]

Operations[edit]

The company's technology, ToleroMune, was initially developed by scientists at Imperial College London.[2] The company is in the process of developing a treatment for cat allergies.[4]

References[edit]

  1. ^ a b c "Accounts for year ended 31 December 2015". Circassia Pharmaceuticals. Retrieved 31 March 2016.
  2. ^ a b "Fundamentals for Circassia Pharmaceuticals Ord 0.08p". The Telegraph. Retrieved 23 August 2014.
  3. ^ "Circassia IPO Fuels Optimism on European Biotech". Wall street Journal. 13 March 2014. Retrieved 23 August 2014.
  4. ^ "Hope of cat allergy cure brings Circassia to stock market". The Telegraph. 6 February 2014. Retrieved 23 August 2014.

External links[edit]